Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
This study has been completed.
Study NCT00045110 Information provided by National Cancer Institute (NCI)
First Received: September 6, 2002 Last Updated: July 10, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Central Nervous System Neoplasms
Glioma
Meningioma
Nervous System Neoplasms
Recurrence
More general conditions related to this trial
Disease Attributes
Meningeal Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neoplasms, Vascular Tissue
Nervous System Diseases
Neuroectodermal Tumors
Pathologic Processes
Interventions listed in this trial
erlotinib hydrochloride
Additional drug interventions recognized in this trial
Erlotinib
More general drug interventions related to this trial
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Sponsors listed in this trial
North American Brain Tumor Consortium
National Cancer Institute (NCI)
Back to top of Main Content
